|
Management
Yoshinari Kumagai
President, Chief Executive Officer and Director
David M. Rosen, Ph.D.
Senior Vice President, Research and Development
Dawn McGuire, M.D.
Chief Medical Officer
Yoshinari Kumagai
President, Chief Executive Officer and
Director
Yoshinari Kumagai has served as President, Chief Executive Officer and Director of Acologix since its inception in May 1992. Prior to founding Acologix, from 1988 to 1992, Mr. Kumagai served as General Manager of Research and Development, Corporate Secretary and Treasurer of Gemini Science, Inc. Previously, he worked for Kirin-Amgen, Inc., a joint venture between Kirin Brewery Co., Ltd. and Amgen, Inc. Mr. Kumagai was also an interim board member of the La Jolla Institute for Allergy and Immunology and played key roles when the institute started its operation in 1989. Mr. Kumagai graduated from Waseda University, School of Science and Engineering with a B.S. in Chemical Engineering.
Top
David M. Rosen, Ph.D.
Senior Vice President, Research and Development
David M. Rosen, Ph.D., has served as Senior Vice President, Research and Development for Acologix since April 2006 and, prior to that, from August 2002 to March 2006, as Vice President, Research and Development. Previously, from March 1999 to July 2002, Dr. Rosen served as Vice President of Operations for Hyseq Pharmaceuticals. He has also held key research and development management and executive positions in public biopharmaceutical companies such as Collagen Corporation and Celtrix Pharmaceuticals. Dr. Rosen earned a B.S. and Ph.D. in Biochemistry from the University of California, Riverside.
Top
Dawn McGuire, M.D.
Chief Medical Officer
Dawn McGuire, M.D. serves as the Company’s Chief Medical Officer. As a board certified neurologist with more than a decade of executive leadership in drug development, Dr. McGuire brings substantial expertise in therapeutic product development for Acologix’ product pipeline. Prior to joining Acologix, Dr. McGuire was the Chief Medical Officer of Pepgen Corporation. Dr. McGuire was also formerly Chief Medical Officer of Avigen, Inc. At Elan Pharmaceuticals, she was Vice President of Clinical Research, where she served as development leader for Tysabri, a drug now marketed for the treatment of patients with relapsing forms of multiple sclerosis (MS). From 1999 to 2002, Dr. McGuire served as Chief Executive Officer of Eunoe, Inc. Dr. McGuire also holds several academic and service positions, including neurological academy committee memberships, peer review committee membership in the National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH), and serves on the Advisory Council of the Gill Heart Institute. Dr. McGuire received her B.A. with high honors from Princeton University and her M.D. from Columbia University, College of Physicians & Surgeons. She was trained in Neurology at the University of California, San Francisco, followed by an NIH-funded postdoctoral fellowship in clinical trial design and experimental therapeutics.
Top
| 
